Aptamer Conjugate

Currently, new drug development companies are having difficulty targeting indications other than liver disease using naked siRNA.

However, Curigin is developing RNAi therapies capable of targeting multiple indications by using an aptamer-conjugate that can bind to specific cell membrane proteins.

An aptamer-conjugated siRNA has a relatively simple manufacturing process since both the aptamer and siRNA components are composed of nucleotides. Moreover, application of the aptamer can be expected to enhance not only the targeting capability of siRNA, but also its efficacy as a competitive inhibitor.